Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 122

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 122
---
 issued patents.
The main composition of matter patents claim protein-polymer conjugates of an extracellular matrix protein (e.g. fibrinogen) or a serum
protein, (e.g., albumin) covalently bound to a synthetic polymer (e.g. polyethylene glycol, polaxamer), as well as uses of these compositions
for treating cartilage injuries or osteoarthritis and scaffolds formed from these conjugates. Additionally, there is a family of patents
claiming a unique device for effective administration of the compositions to the patient and supplies a source of UVA irradiation that
initiates the crosslinking to form the scaffolds.

The scope of the claims of
the granted/issued patents covers both GelrinC and GelrinP, including their uses and processes for making them, as well as supplementary
protection for a specific device for administration of the compositions. In addition, there are additional pending families of applications
that may provide supplementary levels of protection for improvements in the products and the processes of manufacture.

Specifically, while the
basic patent estate (patent family derived from WO 2005/061018) has expiration dates in December 2025, additional patent families of
the Company, have later expiration dates, and cover improvements as detailed herein. In particular, while the basic patent estate is
directed to the specific ingredients of GelrinC, the latest family of patents and patent applications (derived from WO 2017/103924)
is instead directed to a final product; however, the latest patent applications derived from WO 2017/103924 have only been granted
in China and the other patent applications may not mature into actual patents. The final product uses a ready–for–use
formulation technology and the process of manufacture of the final product avoids the use of acetone, which may become forbidden
under advanced guidelines for products introduced into the body. Therefore, we believe that upon approval in different territories,
additional patents could provide the Company with sufficient protection from completion even after the expiration dates of the basic
patent estate.

GelrinC

GelrinC utilizes a conjugate
of denatured fibrinogen and polyethylene glycol and the intended clinical use of this product is to treat focal cartilage injuries. These
specific conjugate molecules are disclosed and claimed in the earliest patent family of the Company derived from WO 2005/061018, which
are nominally due to expire in December